These Analysts Slash Their Forecasts On Haemonetics After Q1 Results

Haemonetics (HAE) reported a strong first quarter, exceeding analyst consensus with EPS of $1.10 (vs. $1.02 est.) and sales of $321.394 million (vs. $305.115 million est.), while affirming its FY2026 adjusted EPS guidance. Despite the positive earnings beat, several analysts adjusted their price targets downwards; JP Morgan downgraded the stock from Overweight to Neutral, lowering its target from $85 to $62, and Mizuho and Barrington Research also reduced their targets, signaling a cautious re-evaluation of valuation despite the strong quarterly performance.

Analysis

Haemonetics (HAE) reported a strong first quarter, with both revenue and earnings per share significantly exceeding analyst expectations. The company posted sales of $321.4 million, beating the $305.1 million consensus, while its EPS of $1.10 surpassed the $1.02 estimate. Furthermore, Haemonetics affirmed its fiscal year 2026 adjusted EPS guidance of $4.70 to $5.00, signaling confidence in its longer-term operational targets. Despite these positive fundamental results, the post-earnings reaction from sell-side analysts was notably cautious. This divergence is highlighted by JP Morgan's decision to downgrade the stock from Overweight to Neutral and slash its price target from $85 to $62. While other analysts at Mizuho and Barrington Research maintained Outperform ratings, they also made substantial reductions to their price targets. This collective downward revision suggests that despite the current operational strength, there are underlying concerns regarding the company's valuation or forward-looking trajectory that have prompted a significant re-rating of the stock's potential.

Key Decisions for Investors

• Investors should investigate the underlying rationale for the analyst price target reductions, as the cautious sentiment contrasts sharply with the company's strong reported earnings and sales beat.
• The affirmation of FY2026 guidance serves as a key fundamental anchor; progress towards the $4.70-$5.00 EPS range should be closely monitored to assess whether current analyst pessimism is warranted.
• Consider the significant signal from JP Morgan's downgrade to Neutral, which suggests that despite the positive quarter, near-term upside may be capped and risks to the stock's valuation have increased.